[{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Brain and Cognition Discovery Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific to Start Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Braxia Scientific
Clinically meaningful improvements in depression severity observed for Psilocybin (as measured by the MADRS1) with complete analysis of antidepressant efficacy and secondary outcomes pending.
The first discussion titled Ketamine and Esketamine, is s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers (mirror image molecules), for the treatment of depression in adults who have tried other antidepressant medicines .
Numerous clinical trials have demonstrated that IV ketamine has rapid and robust antidepressant effects in individuals who continue to suffer from depression, despite trying numerous antidepressant medications and psychotherapy.
As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific's team of researchers also continue to carry out multiple psychedelic-based clinical research trials.
Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment.
Ketamine has been almost exclusively studied as an antidepressant adjunct to other antidepressants. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.
First multiple-dose psilocybin clinical trial will be conducted at Braxia Health's Canadian Rapid Treatment Centers. Trial will include adults with treatment-resistant depression and will also enroll adults who have previously tried electroconvulsive therapy.
The fully funded study, representing the largest registered trial of its kind in the world, will investigate the use, safety and efficacy of repeated doses of intravenous (IV) Ketamine in patients with Bipolar Depression.